Pritzker L B, Scatena M, Giachelli C M
Department of Bioengineering, University of Washington, Box 351720, Seattle, Washington 98195-1720, USA.
Mol Biol Cell. 2004 Jun;15(6):2834-41. doi: 10.1091/mbc.e04-01-0059. Epub 2004 Apr 2.
Endothelial cell survival and antiapoptotic pathways, including those stimulated by extracellular matrix, are critical regulators of vasculogenesis, angiogenesis, endothelial repair, and shear-stress-induced endothelial activation. One of these pathways is mediated by alpha(v)beta(3) integrin ligation, downstream activation of nuclear factor-kappaB, and subsequent up-regulation of osteoprotegerin (OPG). In this study, the mechanism by which OPG protects endothelial cells from death was examined. Serum-starved human microvascular endothelial cells (HMECs) plated on the alpha(v)beta(3) ligand osteopontin were protected from cell death. Immunoprecipitation experiments indicated that OPG formed a complex with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in HMECs under these conditions. Furthermore, inhibitors of TRAIL, including recombinant soluble TRAIL receptors and a neutralizing antibody against TRAIL, blocked apoptosis of serum-starved HMECs plated on the nonintegrin attachment factor poly-d-lysine. Whereas TRAIL was unable to induce apoptosis in HMECs plated on osteopontin, the addition of recombinant TRAIL did increase the percentage of apoptotic HMECs plated on poly-d-lysine. This evidence indicates that OPG blocks endothelial cell apoptosis through binding TRAIL and preventing its interaction with death-inducing TRAIL-receptors
内皮细胞存活和抗凋亡途径,包括那些由细胞外基质刺激的途径,是血管生成、血管新生、内皮修复以及剪切应力诱导的内皮激活的关键调节因子。其中一条途径由α(v)β(3)整合素连接介导,下游核因子-κB激活,随后骨保护素(OPG)上调。在本研究中,研究了OPG保护内皮细胞免于死亡的机制。接种于α(v)β(3)配体骨桥蛋白上的血清饥饿的人微血管内皮细胞(HMECs)可免于细胞死亡。免疫沉淀实验表明,在这些条件下,OPG在HMECs中与肿瘤坏死因子相关凋亡诱导配体(TRAIL)形成复合物。此外,TRAIL抑制剂,包括重组可溶性TRAIL受体和抗TRAIL中和抗体,可阻断接种于非整合素黏附因子聚-d-赖氨酸上的血清饥饿HMECs的凋亡。虽然TRAIL不能诱导接种于骨桥蛋白上的HMECs凋亡,但添加重组TRAIL确实增加了接种于聚-d-赖氨酸上的凋亡HMECs的百分比。这一证据表明,OPG通过结合TRAIL并阻止其与诱导死亡的TRAIL受体相互作用来阻断内皮细胞凋亡